U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Skipping your dose to over-indulge could leave you “excusing yourself from the table in a hurry,” an expert tells PEOPLE ...

Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other weight ...

Two in three adults in England are overweight or obese - and 26 per cent of us have learned all we know about treatments like ...

The study found that semaglutide, sold under brand names Ozempic and Wegovy reduced the hospitalization risk by 22% in alcoholic patients. Ozempic had earlier been shown to mitigate joint pain.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.